Neglected brain region could play a critical role in drug relapse

The FDA is re­open­ing the com­ment pe­ri­od on its dis­cus­sion pa­per on us­ing ar­ti­fi­cial in­tel­li­gence in drug de­vel­op­ment, co­in­cid­ing with a two-day work­shop on the

The panel discussion featuring (L-R) Lucie Ellis-Taitt, executive director In Vivo Citeline, Jean-Paul Kress, CEO, Morphosys and Susanne Schaffert, board director, Novo Holding, Incyte, Galapagos,